CTRI/2015/04/005688已完成1 期
A Phase I/II (Pilot) Trial to Evaluate the Safety and Immunogenicity of HBI Pentavalent (DTwP-Hb-Hib [Liquid]) Combination Vaccine in two groups of Healthy Subjects from 16 Months to 24 Months of Age and Two Years to Five Years of Age.
Human Biologicals Institute0 个研究点目标入组 55 人开始时间: 待定最近更新:
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 55
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1.Healthy children between 16 months and five years of age who have not received booster dose or have received booster dose >1 year earlier
- •2.Subjects who have received primary immunization as per EPI schedule
- •3.Born after a normal gestational period (36 â?? 42 weeks) with a birth weight >=2.5 kg
- •4.Judged to be in good health on the basis of reported medical history and history-directed physical examination
- •5.Plans to remain in the study area for the length of the trial
- •6.Parent or legally acceptable representative has provided Informed consent as per Schedule Y and Indian GCP guidelines.
排除标准
- •1.Participation in another clinical trial in the 4 weeks preceding the trial vaccination
- •2.Planned participation in another clinical trial during the present trial period
- •3.Infant born to known HIV I&II seropositive mother (documented laboratory result of HIV assay from the maternal blood sample is available)
- •4.Previous evidence of infection with Diphtheria, Tetanus, Pertussis Hepatitis B and H. influenzae
- •5.History of allergic disease or reaction likely to be exacerbated by any component of the study vaccines including allergy to antibiotics
- •6.Children having any intercurrent illness
- •7.Evidence of evolving neurological signs and symptoms
- •8.Known or suspected primary or acquired disease of the immune system
- •9.Malignancy, allergy immunotherapy, or receiving immunosuppressive therapy (participants who are taking topical and inhaled steroids could be included in the study as would participants on a â??short courseâ?? of oral steroids, <7 days, as long as there are not two courses within the previous two weeks prior to vaccination)
- •10.Any unstable significant underlying chronic disease, including (but not limited to) malignancy, cardiopulmonary disease, renal, endocrinologic, hematologic or hepatic dysfunction
- •11.Known impairment of neurologic function or currently active seizure disorder or currently requiring medication for seizures
- •12.Receipt of blood products or immunoglobulin by mother in any trimester or by the child since birth
- •13.Daily use of non-steroidal anti-inflammatory drugs
- •14.Receipt of any vaccine other than OPV, BCG and or investigational product within the 30 days prior to enrollment, or planning to receive any other vaccine within 28 days after receiving study vaccine
- •15.Known or suspected acute infectious respiratory illness at the time of vaccination with active symptoms and signs including one or more of the following: rhinorrhea, new cough, pharyngitis and respiratory problems (e.g. wheezing, shortness of breath)
- •16.Any condition which, in the opinion of the investigator, would pose a health risk to the participant or interfere with the evaluation of the vaccine
- •17.History of immediate anaphylaxis, encephalopathy within 7 days, or seizure within 3 days of receiving diphtheria, tetanus, or pertussis and Hepatitis B vaccine in a sibling
- •18.Thrombocytopenia or bleeding disorder that would pose as a contraindication to an IM vaccination.
研究者
相似试验
已完成
2 期
A Phase 1b/2a Pilot Study to Evaluate the Safety and Tolerability of Autologous T-Cells Expressing Enhanced TCRs (T Cell Receptors) Specific for NY-ESO-1/LAGE-1a (GSK3377794) Alone, or in Combination with Pembrolizumab in HLA-A2+ Participants with NY-ESO-1- or LAGE-1a-Positive Advanced or Recurrent Non-Small Cell Lung Cancer (study 208471)lung cancerNL-OMON52531GlaxoSmithKline9
进行中（未招募）
1 期
A study of NY-ESO-1 T-cells (GSK3377794) alone and in combination with Pembrolizumab in NSCLC patients.EUCTR2018-003949-42-NLGlaxoSmithKline Research & Development Ltd54
进行中（未招募）
1 期
A phase I/II feasability trial to assess the safety, immunological activity and efficacy of TroVax plus interferon alpha in patients with advanced or metastatic renal cell cancer.Advanced or Metastatic Renal Cell CancerEUCTR2006-000753-22-GBOxford MioMedica UK Ltd.10
进行中（未招募）
不适用
Safety and Effect of the Histone Deacetylase Inhibitor Romidepsin and the Therapeutic Vaccine Vacc-4x for Reduction of the Latent HIV ReservoirHIV-infectionMedDRA version: 17.1Level: LLTClassification code 10008919Term: Chronic HIV infectionSystem Organ Class: 100000004862EUCTR2013-004747-23-DKBionor Pharma ASA
招募中
不适用
A Study to Evaluate Immunotherapy Combinations in Participants with Lung CancerNeoplasmsKCT0004139ovotech Asia Korea45